3rd Quarter - Report

CELGENE CORPORATION for CELGENE CORPORATION

Firm
Client
Income
—
Expenses
$790,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

S. 1390, "STRONGER Patents Act of 2017", provisions regarding patent reform.

LobbyistCovered position, as disclosed
PATRICK GLIHA —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 1390 (115th)

Health Issues HCR

H.R. 2051, "FAST Generics Act of 2017", provisions regarding REMS. H.R. 1409, "Cancer Drug Parity Act of 2017", regarding all provisions. H.R. 2077, "Restoring the Patient's Voice Act of 2017", Step Therapy / Fail First. S. 974/ H.R. 2212, "CREATES Act of 2017", provisions regarding REMS. Issues relating to Cancer Drug Coverage Parity. Issues relating to Step Therapy / Fail First. Issues relating to Medicare Part D / Part B. Issues relating to Medicare Reimbursement for Transformative Therapies.

LobbyistCovered position, as disclosed
GREG CHESMORE —
PATRICK GLIHA —
STEPHEN RUBRIGHT —
MATTHEW SCHUMAKER —
ALANNA TEMME New Legislative Director - Office of Jon C. Porter January 2006-December 2008 Legislative Assistant - Committee on Education and the Workforce - August 2003- July 2004 Staff Assistant - Committee on Financial Services - August 2002-July 2003.

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1409 (115th), H.R. 2051 (115th), H.R. 2077 (115th), H.R. 2212 (115th), S. 974 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.